Lawmakers Warn U.S. Lags Behind China in Biotech

Officials discussed national security risks and supply chain dependencies during an Axios event in Washington.

Updated on Sept. 25, 2026 in Biotech

Bold flat-color editorial illustration in deep red and cream showing clinical glass vials, evoking the complexity of U.S. pharmaceutical supply chains.
Senator Todd Young and other officials warned that U.S. reliance on Chinese biomanufacturing capabilities presents significant national security risks to the pharmaceutical supply chain. AI Illustration. Upload story photo >

Live Poll

Should the U.S. prioritize biomanufacturing self-sufficiency over maintaining collaborative research ties with foreign nations?

Senator Todd Young warned that China currently leads the United States in critical biomanufacturing capabilities. The remarks underscore rising concerns over the U.S. reliance on Chinese supply chains for essential pharmaceuticals.

Why it matters

The U.S. biopharma sector remains heavily dependent on China, creating vulnerabilities that impact both national security and patient access to medicine. Biotech advancements drive drug development but simultaneously introduce new threats to warfighters.

Genentech has implemented artificial intelligence to compress early-stage research timelines from years to months. These AI-driven workflows are increasingly vital for maintaining a competitive edge in the domestic biotech arena.

The players

Todd Young

He is a U.S. Senator who has focused on the intersection of technological competition and national security.

April McClain Delaney

She is a U.S. Representative who monitors federal resource allocation in the biotech industry.

Maria Ghazal

She serves as a spokesperson for the industry and has highlighted the risks of restricting international collaboration.

Genentech

This biotechnology corporation specializes in utilizing artificial intelligence to accelerate its drug research processes.

The details

During a September 23, 2026, Axios event, panelists explored the risks of relying on Chinese biotech firms while balancing the need for global innovation. While some officials advocated for tighter restrictions, others like Maria Ghazal warned that limiting collaboration could stall life-saving drug development for U.S. patients.

Timeline

  1. The Axios event took place on September 23, 2026.

The Tech Race

The push to secure U.S. biomanufacturing signals a pivot toward treating medical supply chains as critical national security infrastructure. This approach follows the logic of the U.S.-China AI safety hotline, which seeks to establish guardrails for sensitive emerging technologies.

A potential decoupling from Chinese biotech could lead to shifts in drug availability and pricing for U.S. patients as domestic supply chains are restructured. Readers may see changes in how pharmaceutical companies integrate AI to speed up the development of new treatments.

The takeaway

Maintaining a competitive edge in biotech requires a balance between aggressive national security policy and the need for global research collaboration. The industry is currently moving toward an AI-integrated model to stay competitive in the face of rising global rivals.

Further reading

For more on industry developments, visit the Biotech section.

Source note: This article includes information reported by Axios.

Live Poll

Should the U.S. prioritize biomanufacturing self-sufficiency over maintaining collaborative research ties with foreign nations?